ASCEND-Eye:阿司匹林对糖尿病视网膜病变的影响
每日 100 mg 阿司匹林组与安慰剂组在平均 6.5 年随访中,可转诊病变发生率无显著差异(率比 1.03,95%CI 0.91-1.16,P=0.64),威胁视力的眼出血率比 0.89(95%CI 0.62-1.27)。数据排除阿司匹林对糖尿病视网膜病变有任何临床意义获益,但对其眼科安全性给予保证。
要点
- 每日 100 mg 阿司匹林未显著降低可转诊糖尿病视网膜病变发生率(率比 1.03,95%CI 0.91-1.16,P=0.64)。
- 威胁视力的眼出血事件两组无显著差异(阿司匹林组 0.7% vs 安慰剂组 0.8%,率比 0.89,95%CI 0.62-1.27)。
- 数据排除阿司匹林对糖尿病视网膜病变的任何临床意义获益,并为其眼科安全性提供保证。
核心结论
- 这些数据排除阿司匹林对糖尿病视网膜病变的任何临床意义获益,但对其眼科安全性给予保证。
研究设计与样本
- ASCEND 双盲、随机、安慰剂对照试验的子研究,每日 100 mg 阿司匹林用于糖尿病患者严重心血管事件的一级预防。
- 采用对数秩方法进行意向性治疗分析,分析至首次主要疗效和安全结局的时间;获得 7360 名参与者(占 ASCEND 随机化人群 48%)的链接数据。
主要发现
- 平均随访 6.5 年期间,阿司匹林组 539 名参与者(14.6%)发生可转诊疾病事件,安慰剂组 522 名(14.2%)(率比 1.03;95%CI 0.91-1.16;P=0.64)。
- 威胁视力的眼出血事件比例无统计学显著组间差异(阿司匹林组 57 名[0.7%] vs 安慰剂组 64 名[0.8%];率比 0.89;95%CI 0.62-1.27)。
关键数值与推荐
- 主要疗效终点为随机化后首次记录的的可转诊疾病,即可转诊视网膜病变或可转诊黄斑病变的复合终点,依据英国国家筛查委员会定义的 grading 标准。
- 主要安全结局为首次威胁视力的眼出血,定义为导致未缓解视力丧失或需紧急干预(如激光光凝、玻璃体视网膜手术、眼内注射或其组合)的临床显著眼出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preclinical studies support a protective role for aspirin in early diabetic retinopathy (DR), but the findings from randomized trials are limited. We present randomized evidence for the efficacy and safety of aspirin on DR outcomes. DESIGN: A substudy of the A Study of Cardiovascular Events in Diabetes (ASCEND) double-masked, randomized, placebo-controlled trial of 100 mg aspirin daily for the primary prevention of serious cardiovascular events in people with diabetes. PARTICIPANTS: Fifteen thousand four hundred eighty United Kingdom adults at least 40 years of age with diabetes. METHODS: Linkage to electronic National Health Service Diabetic Eye Screening Programme records in England and Wales and confirmation of participant-reported eye events via medical record review were carried out. Log-rank methods were used for intention-to-treat analyses of time until the first primary efficacy and safety outcomes. MAIN OUTCOME MEASURES: The primary efficacy end point was the first record of referable disease after randomization, a composite of referable retinopathy or referable maculopathy based on the grading criteria defined by the United Kingdom National Screening Committee. The primary safety outcome was the first sight-threatening eye bleed, defined as clinically significant bleeding in the eye that resulted in unresolved visual loss or required an urgent intervention such as laser photocoagulation, vitreoretinal surgery, intraocular injection, or a combination thereof. RESULTS: Linkage data were obtained for 7360 participants (48% of those randomized in ASCEND). During the mean follow-up of 6.5 years, 539 participants (14.6%) experienced a referable disease event in the aspirin group, compared with 522 participants (14.2%) in the placebo group (rate ratio, 1.03; 95% confidence interval [CI], 0.91-1.16; P = 0.64). No statistically significant between-group difference was found in the proportions of sight-threatening eye bleed events (57 participants [0.7%] and 64 participants [0.8%], respectively; rate ratio, 0.89; 95% CI, 0.62-1.27). DISCUSSION: These data exclude any clinically meaningful benefits of aspirin for DR, but give reassurance regarding the ophthalmologic safety of aspirin. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Sammons EL, Buck G, Bowman LJ, et al. ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy. Ophthalmology. 2024. PMID: 38237868. doi:10.1016/j.ophtha.2024.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。